⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL449195 | 0.81 | ALDH1A1 (0.52) | — | |
| SCHEMBL452372 | 0.81 | HCAR2 (0.42) | — | |
| SCHEMBL21750379 | 0.79 | ALDH1A1 (0.63) | — | |
| SCHEMBL21809422 | 0.79 | ALDH1A1 (0.63) | — | |
| SCHEMBL8692097 | 0.78 | ALDH1A1 (0.32) | — | |
| SCHEMBL451520 | 0.78 | ATM (0.52) | — | |
| SCHEMBL451856 | 0.78 | TSHR (0.45) | — | |
| SCHEMBL449511 | 0.78 | ALDH1A1 (0.48) | — | |
| SCHEMBL450560 | 0.77 | — | — | |
| SCHEMBL23198 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 265 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240131180-A1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR, S.A. (ES) | 2024-04-25 | — | — | US | disclosed |
| EP-4025253-B1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR SA (ES) | 2024-03-20 | — | — | EP | disclosed |
| CN-114615999-B | Drug antibody conjugates | 法马马有限公司 | 2024-03-08 | — | — | CN | disclosed |
| US-20230218774-A1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR, S.A. (ES) | 2023-07-13 | — | — | US | disclosed |
| EP-4138923-A1 | DRUG ANTIBODY CONJUGATES | Pharma Mar, S.A. (ES) | 2023-03-01 | — | — | EP | disclosed |
| US-20230012681-A1 | ANTIBODY DRUG CONJUGATES COMPRISING ECTEINASCIDIN DERIVATIVES | PHARMA MAR, S.A. (ES) | 2023-01-19 | — | — | US | disclosed |
| EP-3870234-B1 | ANTIBODY DRUG CONJUGATES COMPRISING ECTEINASCIDIN DERIVATIVES | PHARMA MAR SA (ES) | 2022-12-21 | — | — | EP | disclosed |
| EP-4025253-A1 | DRUG ANTIBODY CONJUGATES | Pharma Mar S.A. (ES) | 2022-07-13 | — | — | EP | disclosed |
| CN-114615999-A | Drug antibody conjugates | 法马马有限公司 | 2022-06-10 | — | — | CN | disclosed |
| US-20220168436-A1 | ANTIBODY DRUG CONJUGATES | PHARMA MAR SA (ES) | 2022-06-02 | — | — | US | disclosed |
| WO-1996003377-A1 | HETEROCYCLIC COMPOUNDS, USEFUL AS ALLOSTERIC EFFECTORS AT MUSCARINIC RECEPTORS | SANKYO COMPANY, LIMITED (JP) | 1996-02-08 | — | — | WO | disclosed |
| WO-1995033761-A1 | STEROID DERIVATIVES FOR TREATMENT OF 5 ALPHA REDUCTASE | SMITHKLINE BEECHAM CORPORATION (US) | 1995-12-14 | — | — | WO | disclosed |
| US-5459148-A | Cardiovascular disorders | SANKYO COMPANY, LIMITED (JP) | 1995-10-17 | — | — | US | disclosed |
| EP-0628559-A1 | Pyrimidine compounds and their use as pharmaceuticals | Beiersdorf-Lilly GmbH (DE) | 1994-12-14 | — | — | EP | disclosed |
| EP-0609058-A2 | Hexahydronaphthalene ester derivatives, their preparation and their therapeutic uses | SANKYO COMPANY LIMITED (JP) | 1994-08-03 | — | — | EP | disclosed |
| EP-0603001-A1 | Biphenyl derivatives, their preparation and their use for the treatment of hypertension and cardiac disease | SANKYO COMPANY LIMITED (JP) | 1994-06-22 | — | — | EP | disclosed |
| EP-0573218-A2 | 4-Carboxyimidazoles as angiotensin II antagonists and their thrapeutic use | SANKYO COMPANY LIMITED (JP) | 1993-12-08 | — | — | EP | disclosed |
| EP-0567271-A2 | Steroid derivatives for the treatment of prostatic hypertrophy, their preparation and uses | SANKYO COMPANY LIMITED (JP) | 1993-10-27 | — | — | EP | disclosed |
| EP-0545912-A2 | 1-Biphenylmethylimidazole derivatives, their preparation and their therapeutic use | Sankyo Company Limited (JP) | 1993-06-09 | — | — | EP | disclosed |
| EP-0503785-A1 | 1-Biphenylimidazole derivatives, their preparation and their therapeutic use | Sankyo Company Limited (JP) | 1992-09-16 | — | — | EP | disclosed |